Introduction
Antimicrobial resistance has become a serious problem worldwide, especially in Asia. (1) Indonesia is one of the Asian countries where the prevalence of multi drugresistant organisms (MDRO) is very high. The high resistance rates is mainly found in Gram-negative bacteria such as Pseudomonas aeruginosa, Enterobacteriaceae and Acinetobacter baumannii. The same situation applies in animal farms. ( 2) The resistance rates of Klebsiella pneumoniae, Klebsiella ozaenae and Escherichia coli isolated from Intensive Care Unit (ICU) of Fatmawati Hospital were 75.7%, 81.5% and 46.2% to Ceftriaxone; 67.9%, 100% and 46.2% to Cefotaxime; 73%, 85.7% and 38.5% to Ceftazidime.(3) In the ICU of Cipto Mangunkusumo Hospita, Jakarta, however, the prevalence of carbapenem resistant i.e., Enterobacteriaceae 27.6%, P. aeruginosa 21.9% and A. baumannii 50.5%. (4) The major mechanism of resistance of Gram-negative bacteria is from the production of β-lactamases, such as AmpC β-lactamases (AmpC) and extended spectrum β-lactamases (ESBL). (5) The AmpC producers confer resistance to penicillins, cephamycins (i.e., Cefoxitin, Cefotetan), oxyimino-cephalosporins (i.e., Ceftazidime, Cefotaxime, Ceftriaxone) and monobactams (i.e., Aztreonam). This type of microorganism shows resistant to antibiotic combination of β-lactam and β-lactamase inhibitors i.e., Amoxicillin/Clavulanic acid. The AmpC β-lactamases are chromosomal-mediated, and many Gram-Negative bacteria such as Enterobacter spp., Citrobacter spp., Serratia spp., Morganella morganii, Aeromonas spp. and Hafnia alvei have been known to produce AmpC β-lactamases. (6, 7, 8) The widely use of β-lactam antibiotics and β-lactamase inhibitors induces a high level expression of chromosomalmediated AmpC and causes the resistant to among other the 3 rd generation of cephalosporin and carbapenem. In hospitals where 3 rd generation cephalosporins are being used repeatedly for a long period of time, the problem of antibiotic resistance arise. Enterobacter aerogenes and Enterobacter cloacae which are initially susceptible to 3 rd generation cephalosporins have become resistant upon therapy. (8) Apart from the chromosomal gene, the AmpC is also encoded by the plasmid. Gram-negative bacteria such as Klebsiella oxytoca, Proteus mirabilis, Citrobacter freundii and Enterobacter aerogenes are among those with plasmid-mediated AmpC. (8, 9, 10, 11) Differ from chromosomal-mediated AmpC, plasmid-mediated AmpC are expressed significantly, and are typically associated with broad multidrug resistance. (10, 11) The microorganisms that are over expressing AmpC can become resistant to carbapenem when there is disturbance of the outer membrane permeability.(6) At present, 6 types of plasmidmediated ampC gene family has been found, namely DHA (firstly isolated at Dhahran Hospitals in Saudi Arabia), EBC (isolated from Enterobacter cloacae), CIT (firstly isolated from Citrobacter freundii), Ambler class C (ACC), FOX (Active on Cefoxitin), and MOX (Active on Moxalactam).
In the past decades, the prevalence of AmpCproducing Enterobacteriaceae had increased, and resulted in a serious threat, among other these bacteria are the major cause of hospital-acquired infections. (12, 13) However, the information regarding AmpC-producing Enterobacteriaceae originated from hospitalised patients in Indonesia is not available thus far. This study aimed to explore the presence of AmpC-β-lactamase producing Enterobacteriaceae gene family in the ICU of Cipto Mangunkusumo Hospital, Jakarta, and also their antibiotic susceptibility.
Methods
This was a descriptive and cross sectional study. Clinical specimens i.e., blood, lower respiratory tract secretions, urine, wound swabs, pus and soft tissues obtained from adult patients with infection in the ICU of Cipto Mangunkusumo Hospital within 6 months from April to September 2015 were subjected for the investigation. Bacterial cultivation workup was performed in the Clinical Microbiology laboratory of the Department of Microbiology, Faculty of Medicine, Universitas Indonesia. All patients that agreed to give their specimens were enrolled in this study, and signed informed consent.
Bacterial Isolates
Bacterial identification was conducted using VITEK®2 (Bio-Mérieux, Craponne, France). Anti-biotic susceptibility tests were conducted using VITEK®2 for Ampicillin, Gentamicin,
To-bramycin, Amikacin, Ampicillin/ Sulbactam, Piperacillin/Tazobactam, Cefoxitin, Cefotaxime, Ceftazidime, Cefepime, Meropenem, Ciprofloxacin, Levofloxacin, Fosfomycin, Tetracycline, Cotrimoxazole. As for Ceftriaxone, Cefpodoxime, and Aztreonam, disc diffusion technique was employed according to Clinical and Laboratory Standards Institute (CLSI) 2014 guidelines. (14) The antibiotic activity was classified as good if the susceptibility of all isolates to the antibiotic was 80% or greater. Isolates which less susceptible or resistant to one or more of 3 rd generation cephalosporins (i.e., Cefpodoxime, Ceftazidime, Cefotaxime, Ceftriaxone) and/or Aztreonam and/or resistance to Cefoxitin were considered as putative AmpC β-lactamases, ESBL or AmpC/ESBL producers, and were included in this study. These isolates underwent confirmation test i.e., double disc synergy test (DDS) for AmpC β-lactamases and ESBL and subjected to multiplex polymerase chain reaction (PCR) for the detection of ampC gene families.
Confirmation Tests for AmpC β-lactamases and ESBL
Using DDS Test DDS test method using Total ESBL+AmpC kit 98019 (ROSCO Diagnostica, Taastrup, Denmark) was employed to detect AmpC and ESBL activity. The assay was performed according to recommendations in the user manual. Antibiotic discs used were Cefotaxime + Cloxacillin (CTXCX), Cefotaxime + Clavulanate (CTXC), Cefotaxime + Clavulanate + Cloxacillin (CTXCC), Ceftazidime + Cloxacillin (CAZCX), Ceftazidime + Clavulanate (CAZC) and Ceftazidime + Clavulanate + Cloxacillin (CAZCC). Isolates were confirmed as AmpC-producing when the inhibition zone produced around CTXC/CTXCC and/ or CAZC/CAZCC discs was differ ≥ 5 mm. An ESBLproducing was confirmed if the inhibition zone produced around the CTXCX/CTXCC and/or CAZCX/CAZCC discs was ≥ 5 mm. If the inhibition zones produced around CTXCX/CTXCC and the CTXC/CTXCC discs were differ ≥ 5 mm, and/or the CAZCX/CAZCC and CAZC/CAZCC discs were ≥ 5 mm then they were confirmed as producing both AmpC/ESBL enzymes. Escherichia coli ATCC 25922 was used as quality control strain.
The proportion of AmpC and AmpC/ESBL-producing Enterobacteriaceae was determined by dividing the number of those obtained from DDS test with all putative isolates which were less susceptible or resistant to one or more of 3 rd generation cephalosporins and/or Aztreonam and/or resistance to Cefoxitin.
Multiplex PCR for the Identification of AmpC Gene Families
The DNA extraction was performed from fresh culture using boiling techniques. Five to 10 colonies of overnight bacterial culture were suspended into 500 μL of sterile phosphate buffer saline (PBS), mixed on a vortex mixer, and spin at 12,000 rpm for 2 min (2 times). After the supernatant was decanted, the pellet was resuspended in 200 μL of TE buffer and the mixture was briefly mixed on a vortex mixer. The cells were lysed by heating at 90°C for 20 min and cellular debris was removed by centrifugation at 12,000 rpm for 10 min. A 100 μL aliquot of the supernatant was transferred to a sterile tube and stored at -20°C until PCR testing. Multiplex PCR (Philisa® ampC ID Kit, Streck, Inc., La Vista, USA) was conducted to detect 6 different families of plasmidmediated ampC genes i.e., ACC, CIT, DHA, EBC, FOX and MOX, and primers were used as published earlier. (7) The assay was performed according to recommendations in the user manual. The DDS test was employed to these 45 isolates and the results were shown in Table 1 , as follow: Four isolates were the AmpC-producing Enterobacteriaceae i.e., K. pneumoniae (n=1), E. cloacae (n=2), and E. aerogenes (n=1). Thirty three isolates were the ESBL-producers in which K. pneumoniae was the most prominent among other Enterobactericeae. Five isolates were the AmpC/ Results ESBL producers i.e., K. pneumoniae (n=2), E. cloacae (n=2) and E. coli (n=1). Three isolates were non-producing β-lactamases. In brief, out of 45 isolates of the putative AmpC β-lactamases and/or ESBL producers, only 9 (20%) isolates were confirmed by DDS test as the AmpC and AmpC/ESBL producers.
Ethical Clearance
Antibiotic susceptibility tests were carried out as mentioned in the methods for the 42 AmpC, ESBL, and AmpC/ESBL confirmed isolates. Three isolates of the non-producing β-lactamases were not tested. As shown in Tables 2, the AmpC-producing isolates (4 isolates) showed ≥75% susceptibility to Gentamicin, Tobramycin, Amikacin, Cefepime, Meropenem, Ciprofloxacin, Levofloxacin, Tetracycline and Cotrimoxazole. All 5 isolates of the AmpC/ ESBL-producing isolates showed resistant to all antibiotics but to Amikacin.
Gene family of AmpC-producing Enterobacteriaceae was determined by multiplex PCR on all of 45 isolates ( Figure 1) . The results showed that ampC genes were detected in 6 isolates consisted of 4 species i.e., K. pneumoniae, E. cloacae, E. aerogenes and E. coli. The ampC gene families, i.e., DHA, EBC and CIT were identified. DHA gene family was identified from 2 isolates of K. pneumoniae and 1 isolate of E. cloacae. EBC was from 1 isolate each of E. cloacae and of E. aerogenes, and lastly CIT was from 1 isolate of E. coli (Table 3) .
Discussion
This study demonstrates that gene families of AmpCproducing Enterobacteriaceae are present in the ICU of Cipto Mangunkusumo Hospital, Jakarta. The distribution of the total proportion of AmpC-producing Enterobacteriaceae was 20%, consisting of 9 isolates out of 45 putative putative AmpC β-lactamases and/or ESBL producers. The result was quite similar with previous studies carried in India, Singapore and South Korea. (8, 9, 12, 15) Our study showed that among 9 isolates of the AmpC producers, 5 of them produced AmpC and ESBL. Unlike the AmpC/ESBL producers that showed resistant to all antibiotics except for Amikacin, the AmpCproducing isolates were susceptible to many antibiotics such as Gentamicin, Tobramycin, Amikacin, Cefepime, Meropenem, Ciprofloxacin, Levofloxacin, Tetracycline, and Cotrimoxazole. In this study, 1 of the AmpC-producing isolate and 3 AmpC/ESBL-producing isolates showed Up until today, studies about molecular epidemiology of resistance pathogens in Indonesia were still limited. To our knowledge, our study was the first investigation about the gene family of AmpC-producing Enterobacteriaceae in Indonesia. Using the multiplex PCR, DHA, EBC and CIT gene families of the AmpC-producing were identified. The DHA gene family seemed to be more common than EBC and CIT. Our results were in agreement with other studies carried in India that found the CIT and DHA gene families. (9, 10, 11) In Singapore, the presence of CIT gene family was reported while the EBC and DHA gene families have been found in Malaysia. (10, 17) Other reports from Thailand (18) and South Korea (12) showed the presence of CIT, MOX, DHA and CIT respectively.
Hansen, et al., 2012 identified DHA gene family of AmpC-producing K. pneumoniae, however, the β-lactamase was not detected. (19) This condition could have occurred since DHA genes are inducible by β-lactam antibiotics, instead of expressed naturally.(6) Therefore the use of β-lactam antibiotics must be prudent to avoid an expression or even over expression of the ampC plasmid-mediated gene. In this study, ampC genes were only detected in 6 isolates out of 9 confirmed AmpC and AmpC/ESBL producers. This result could be due to the fact that of ampC gene family continue to expand, while the primers used in this study were only designated to these 6 ampC gene families. In addition, they also exist as varian i.e., the varian for the DHA are DHA-1 and DHA-2, the CIT are CMY-2 and CMY-4, the EBC are ACT-1 and MIR-1 and many more. There were some constraints in the present study, among other β-lactamase standard microorganisms for the DDS test was not available. Number of AmpC and AmpC/ ESBL isolates positive from the DDS test was too low, which then might not show the presence of all ampC gene family has ever reported by PCR.
Conclusion
This study showed the AmpC and AmpC/ESBL-producing Enterobacteriaceae were simultaneously co-exist in the ICU of Cipto Mangunkusumo Hospital. Three ampC gene families, DHA, EBC and CIT were identified. All of the AmpC/ESBL-producing isolates showed resistance to almost all antibiotic tested except for Amikacin. Therefore, the use of antibiotics for the treatment of the patients with infection in the ICU must be prudent to prevent the increase and the spread of the multi-drug resistant bacteria.
